Elan sells MS drug; shares drop 8.8%
UPDATE: Biogen Idec agreed to acquire partner Elan’s stake in the multiple sclerosis drug Tysabri for $3.25 billion in cash plus future royalties.
Biogen Idec has agreed to acquire partner Elan’s stake in the multiple sclerosis drug Tysabri for $3.25 billion in cash plus future royalties.
Elan's share price initially soared 11.3 per cent but has since reversed and closed with a loss of 8.8 per cent in Dublin. Analysts said markets were sceptical about Elan's prospects of profitably reinvesting the proceeds.
The deal ends speculation that Biogen would buy Elan and gives Biogen all rights to the drug....
Subscribe from just €1 for the first month!
With any subscription you will have access to
Unlimited multi-device access to our iPad, iPhone and Android Apps
Unlimited access to our eReader library
Exclusive daily insight and opinion seven days a week
Create alerts to never miss a subject that matters to you
Get access to exclusive offers for subscribers on gifts and experiences
Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine